A dose-finding study of the safety and tolerability of intravenous reovirus (REOLYSIN®) (pelareorep) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with standard of care chemoradiotherapy (CTRT) /adjuvant chemotherapy for Glioblastoma Multiforme (GBM)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pelareorep (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 06 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2017 New trial record
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.